Closing the 90% Gap: Biotech's Big Bet on Free Alpha-1 Testing

DURHAM, NC – May 13, 2026 – A groundbreaking partnership announced today aims to solve a decades-old medical mystery: why over 90% of individuals with a serious genetic condition remain undiagnosed. Biotechnology firm Beam Therapeutics has become an inaugural sponsor of AlphaDetect, a new non-profit dedicated to providing free, widespread genetic testing for Alpha-1 Antitrypsin Deficiency (Alpha-1), a progressive and irreversible disease affecting the lungs and liver.

The collaboration represents a major push to overhaul a failing diagnostic landscape, moving beyond awareness campaigns to directly remove the financial and logistical barriers that prevent patients from getting answers. For the thousands living with unexplained lung or liver disease, it offers a clear path to a diagnosis. For Beam Therapeutics, a company developing a potential genetic cure for Alpha-1, the initiative is a strategic investment in identifying the very patients who may one day benefit from its science.

The Hidden Epidemic of Alpha-1

Alpha-1 Antitrypsin Deficiency is the most common known genetic risk factor for Chronic Obstructive Pulmonary Disease (COPD) and is also linked to severe liver disease in both children and adults. Yet, despite its prevalence, it remains a hidden epidemic. The Alpha-1 Foundation estimates that of the millions potentially affected worldwide, the vast majority are unaware they carry the genetic risk. Patients often suffer for years, misdiagnosed with more common ailments like asthma or smoking-related COPD.

The diagnostic delay has "real, irreversible consequences," said Julie Murray, CEO of AlphaDetect, in a statement. The primary barrier is a combination of low awareness and symptom overlap. The wheezing and shortness of breath characteristic of Alpha-1 are nearly indistinguishable from other respiratory conditions, leading physicians to overlook the genetic root cause.

Clinical guidelines from leading bodies like the American Thoracic Society and World Health Organization recommend testing for Alpha-1 in all individuals with COPD, treatment-resistant asthma, or unexplained liver disease. However, real-world adherence to these guidelines is notoriously poor. This gap between recommendation and reality means countless individuals miss the window for early intervention, which can include lifestyle changes, access to support, and existing therapies that can slow disease progression.

"Advancing Alpha-1 detection requires a focused effort," noted Amy Simon, MD, Chief Medical Officer of Beam Therapeutics. "These efforts will help bring much needed answers to patients and their families."

A New Model for Mass Detection

AlphaDetect, a non-profit subsidiary of the long-established Alpha-1 Foundation, was created specifically to bridge this diagnostic chasm. Its model is simple yet radical: eliminate all barriers to testing. The organization will operate its own proprietary laboratory in Durham, providing free genetic test kits to healthcare providers. The cost will be covered entirely by the non-profit and its sponsors, with no charge to patients or insurance companies.

This approach directly tackles the inertia in the healthcare system. By making the test free and easy to administer, AlphaDetect aims to integrate Alpha-1 screening as a routine part of care for at-risk populations. The organization is also building a dedicated engagement team to support medical practices in implementing testing protocols and to answer clinical questions from providers.

The goal is to "scale proven approaches to identifying at-risk patients, quickly and systematically," according to Murray. An early diagnosis does more than just name the condition; it serves as a "point of entry into the Alpha-1 community," as the foundation describes it, unlocking a wealth of resources, patient support networks, and information needed to manage the lifelong journey with the disease.

The Strategic Science Behind the Sponsorship

While the sponsorship has clear philanthropic benefits, it also aligns perfectly with Beam Therapeutics' long-term business strategy. Beam is a pioneer in the field of precision genetic medicine, focusing on a revolutionary technology called base editing. Unlike other gene editing methods, base editing is designed to make precise, single-letter changes to the DNA code without making double-stranded breaks, a process the company likens to a pencil and eraser for the genome.

This technology is at the heart of Beam's lead program for genetic diseases: BEAM-302, a therapy designed to correct the specific gene mutation that causes Alpha-1. The therapy, which received Orphan Drug Designation from the FDA in 2025, aims to be a one-time treatment that addresses both the liver and lung manifestations of the disease by restoring the body's ability to produce the correct AAT protein.

By funding AlphaDetect, Beam is not just supporting the community; it is helping to build the market for its future therapies. A larger pool of diagnosed patients translates directly into a larger population eligible for clinical trials and, eventually, commercial treatment. This "diagnose to treat" model represents a sophisticated fusion of corporate social responsibility and strategic market development, ensuring that when a potential cure is ready, the patients who need it have already been found.

A Shifting Therapeutic Landscape

The partnership arrives at a pivotal moment for Alpha-1 treatment. For decades, the standard of care for lung-related complications has been augmentation therapy, which involves regular infusions of AAT protein derived from donated human plasma. This therapy, offered by companies like Grifols, Takeda, and CSL Behring, helps slow lung deterioration but is costly, burdensome, and does not address the liver disease component or reverse existing damage.

Now, a new wave of innovation is focused on correcting the disease at its source. Alongside Beam's base editing approach, companies like Arrowhead Pharmaceuticals (in partnership with Takeda) and AIRNA are advancing RNA-based therapies designed to silence the faulty gene or edit its messages. This shift from chronic management to potential one-time cures represents a paradigm shift in rare disease treatment.

However, the success of these next-generation therapies is entirely dependent on early and accurate diagnosis. You cannot cure patients you cannot find. In this context, the work of AlphaDetect is not just beneficial but foundational to the entire field.

"This support builds on Beam Therapeutic's commitment to progressive clinical research... and represents an important step forward in how we approach detection," said Scott Santarella, CEO of the Alpha-1 Foundation. By expanding detection efforts, the community can identify more individuals earlier, improving lives today while paving the way for the breakthrough cures of tomorrow.